249 related articles for article (PubMed ID: 23042103)
21. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry.
Begum N; Maasberg S; Pascher A; Plöckinger U; Gress TM; Wurst C; Weber F; Raffel A; Krausch M; Holzer K; Bartsch DK; Musholt TJ; Keck T; Anlauf M; Rinke A; Pape UF; Goretzki PE;
Langenbecks Arch Surg; 2020 Mar; 405(2):145-154. PubMed ID: 32372309
[TBL] [Abstract][Full Text] [Related]
23. Surgery on neuroendocrine tumours.
Akerström G; Hellman P
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):87-109. PubMed ID: 17382267
[TBL] [Abstract][Full Text] [Related]
24. Outcome of surgery for pancreatic neuroendocrine neoplasms.
Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
[TBL] [Abstract][Full Text] [Related]
25. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
26. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study.
Le Treut YP; Grégoire E; Klempnauer J; Belghiti J; Jouve E; Lerut J; Castaing D; Soubrane O; Boillot O; Mantion G; Homayounfar K; Bustamante M; Azoulay D; Wolf P; Krawczyk M; Pascher A; Suc B; Chiche L; de Urbina JO; Mejzlik V; Pascual M; Lodge JP; Gruttadauria S; Paye F; Pruvot FR; Thorban S; Foss A; Adam R;
Ann Surg; 2013 May; 257(5):807-15. PubMed ID: 23532105
[TBL] [Abstract][Full Text] [Related]
27. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK
Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024
[TBL] [Abstract][Full Text] [Related]
28. The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours.
Jernman J; Välimäki MJ; Louhimo J; Haglund C; Arola J
Neuroendocrinology; 2012; 95(4):317-24. PubMed ID: 22327359
[TBL] [Abstract][Full Text] [Related]
29. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.
Borbath I; Garcia-Carbonero R; Bikmukhametov D; Jimenez-Fonseca P; Castaño A; Barkmanova J; Sedlackova E; Kollár A; Christ E; Kaltsas G; Kos-Kudla B; Maasberg S; Verslype C; Pape UF
Eur J Cancer; 2022 Jun; 168():80-90. PubMed ID: 35472579
[TBL] [Abstract][Full Text] [Related]
30. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital.
Rothenstein J; Cleary SP; Pond GR; Dale D; Gallinger S; Moore MJ; Brierley J; Siu LL
Am J Clin Oncol; 2008 Feb; 31(1):64-70. PubMed ID: 18376230
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
Min BH; Hong M; Lee JH; Rhee PL; Sohn TS; Kim S; Kim KM; Kim JJ
Br J Surg; 2018 Oct; 105(11):1480-1486. PubMed ID: 29893418
[TBL] [Abstract][Full Text] [Related]
33. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.
Korse CM; Taal BG; van Velthuysen ML; Visser O
Eur J Cancer; 2013 May; 49(8):1975-83. PubMed ID: 23352435
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland.
Gouffon M; Iff S; Ziegler K; Larche M; Schwarzenbach C; Prior JO; Matter M; Stettler C; Pralong FP
Swiss Med Wkly; 2014 Feb; 144():w13924. PubMed ID: 24554450
[TBL] [Abstract][Full Text] [Related]
35. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
Basu B; Sirohi B; Corrie P
Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
[TBL] [Abstract][Full Text] [Related]
36. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
37. Synchronous resection of primary and liver metastases for neuroendocrine tumors.
Gaujoux S; Gonen M; Tang L; Klimstra D; Brennan MF; D'Angelica M; Dematteo R; Allen PJ; Jarnagin W; Fong Y
Ann Surg Oncol; 2012 Dec; 19(13):4270-7. PubMed ID: 22752376
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine tumours of the duodenum. Clinical aspects, pathomorphology and therapy.
Witzigmann H; Loracher C; Geissler F; Wagner T; Tannapfel A; Uhlmann D; Caca K; Hauss J; Hehl JA
Langenbecks Arch Surg; 2002 Jan; 386(7):525-33. PubMed ID: 11819111
[TBL] [Abstract][Full Text] [Related]
39. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
[TBL] [Abstract][Full Text] [Related]
40. A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012.
Maschmeyer G; Mügge LO; Kämpfe D; Kreibich U; Wilhelm S; Aßmann M; Schwarz M; Kahl C; Köhler S; Grobe N; Niederwieser D
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1639-44. PubMed ID: 25773126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
